Fig. 2. Association between 4F2hc and B3GNT3 expression and prognosis in a large cohort of PDAC patients.
A. 4F2hc and B3GNT3 protein expression in paired tumor and adjacent normal tissues from 6 PDAC patients was determined by western blotting. B Paired comparison of 4F2hc and B3GNT3 protein expression. Statistical significance was determined by a two-tailed paired t-test. C Scatter plots showed the Pearson correlation of IHC scores of 4F2hc and B3GNT3. The purple line was a linear fit changed with the expression of 4F2hc and B3GNT3. D Representative HE (top) and IHC (bottom) stained sections of 4F2hc and B3GNT3 in PDAC (scale bar = 100 μm). Scores 0, 1, 2, and 3 represent negative, low, moderate, and high, respectively. E, F Percentage of patient samples for 4F2hc and B3GNT3 in tumor differentiation and AJCC stage. The correlation between the indicated molecule and the indicated clinicopathological characteristics was analyzed by the chi-square test. G, I, K Kaplan–Meier curves of progression‐free survival (PFS) stratified by 4F2hc (G) and B3GNT3 (I) and combined expression (K). H, J, L Kaplan–Meier curves of disease-specific survival (DSS) stratified by 4F2hc (H) and B3GNT3 (J) and combined expression (L). M Representative multiplex immunohistochemistry images of the spatial distribution and abundance for 4F2hc, B3GNT3, xCT, NRF2, CK, and DAPI in TMAs sections from case 242 of PDAC. Glandular intraepithelial neoplasia, (GIN). Scale bar: 200 µm. Statistical significance among the indicated groups was assessed by a one-tailed t-test, one-sided log-rank test, or Tarone-Ware test. *P < 0.05.